All articles

Positive Sasanlimab Data From Pfizer Could Bring New Medicine For High-Risk Bladder Cancer

Caribou Cuts Workforce And Puts Focus To lead Oncology Candidates

Genentech Aims For DECODE Platform From Repertoire In $765 Million Deal

Bristol-Myers Squibb Fails Phase 3 Study With Cobenfy

In Flight To Enact Strategic Alternatives, Tempest Cuts 80% of its Workforce

Eli Lilly’s Orforglipron Delivers Efficacy Similar To That Of Injectable GLP-1 Drugs

Despite Primary Endpoint Falling Short, Sanofi Moving Amlitelimb Forward

Mural Oncology Mulls Strategic Alternatives After Latest Failure With IL-2 Candidate

Scroll to Top